![Daniel Asse van den Noort](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Asse van den Noort
Directeur/Membre du Conseil chez
CXPro BV
Profil
Daniel Asse van den Noort is currently the Director at CXPro BV and a Member-Supervisory Board at Bluewater Holding BV.
He previously held positions such as Non-Executive Chairman at Verdes Management Plc, Director at CymaBay Therapeutics, Inc., Director at Genizon Biosciences, Inc., Director at Syntarga BV, and Non-Executive Director at EW Group Ltd. He was also the Chief Investment Officer at Biotech Turnaround Fund BV from 2001 to 2010.
Dr. van den Noort holds a doctorate degree from Vrije Universiteit Amsterdam.
Postes actifs de Daniel Asse van den Noort
| Sociétés | Poste | Début |
|---|---|---|
CXPro BV | Directeur/Membre du Conseil | - |
Bluewater Holding BV
 Bluewater Holding BV Oilfield Services/EquipmentIndustrial Services Operates as a holding company with interests in in the supply of services and products to the oil industry | Directeur/Membre du Conseil | - |
Anciens postes connus de Daniel Asse van den Noort
| Sociétés | Poste | Fin |
|---|---|---|
EW Group Ltd.
 EW Group Ltd. Investment Trusts/Mutual FundsMiscellaneous Closed-End Investment Fund/Investment Trust | Directeur/Membre du Conseil | 07/05/2014 |
Verdes Management Plc
 Verdes Management Plc Financial ConglomeratesFinance Operates as investment company | Président | 26/03/2014 |
Genizon Biosciences, Inc.
 Genizon Biosciences, Inc. BiotechnologyHealth Technology Provides drug development services | Directeur/Membre du Conseil | 30/05/2012 |
Biotech Turnaround Fund BV
 Biotech Turnaround Fund BV Investment ManagersFinance BTF's investment strategy focuses on value creation. They are long-term investors. They concentrate on limited number of late-stage firms in the biotechnology sector primarily in Europe and North America. In a top-down screening process, they target firms in what they term the turnaround phase: when the portfolio firm has drug development candidates in phase II clinical trials. Specifically, they have structured their portfolio around human monoclonal antibodies, nuclear receptor drugs for diabetes, and population genetics. BTF is an active, vocal investment partner. They use a hands-on portfolio management style and require a Board member seat. Through their advisory board members and pool of business advisors, they share knowledge and contacts with their portfolio firms' management teams. Their investment horizon is typically three years. | Private Equity Investor | 01/08/2010 |
Syntarga BV
 Syntarga BV Pharmaceuticals: MajorHealth Technology Engages in the discovery and development of cell-killing drugs, releasable linker technologies, and linker-drug combinations | Directeur/Membre du Conseil | - |
Formation de Daniel Asse van den Noort
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
8
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for people with life-threatening diseases | Health Technology |
Bluewater Holding BV
Bluewater Holding BV Oilfield Services/EquipmentIndustrial Services Operates as a holding company with interests in in the supply of services and products to the oil industry | Industrial Services |
Genizon Biosciences, Inc.
Genizon Biosciences, Inc. BiotechnologyHealth Technology Provides drug development services | Health Technology |
Verdes Management Plc
Verdes Management Plc Financial ConglomeratesFinance Operates as investment company | Finance |
Biotech Turnaround Fund BV
Biotech Turnaround Fund BV Investment ManagersFinance BTF's investment strategy focuses on value creation. They are long-term investors. They concentrate on limited number of late-stage firms in the biotechnology sector primarily in Europe and North America. In a top-down screening process, they target firms in what they term the turnaround phase: when the portfolio firm has drug development candidates in phase II clinical trials. Specifically, they have structured their portfolio around human monoclonal antibodies, nuclear receptor drugs for diabetes, and population genetics. BTF is an active, vocal investment partner. They use a hands-on portfolio management style and require a Board member seat. Through their advisory board members and pool of business advisors, they share knowledge and contacts with their portfolio firms' management teams. Their investment horizon is typically three years. | Finance |
Vrije Universiteit Amsterdam
 Vrije Universiteit Amsterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Syntarga BV
Syntarga BV Pharmaceuticals: MajorHealth Technology Engages in the discovery and development of cell-killing drugs, releasable linker technologies, and linker-drug combinations | Health Technology |
EW Group Ltd.
EW Group Ltd. Investment Trusts/Mutual FundsMiscellaneous Closed-End Investment Fund/Investment Trust | Miscellaneous |
CXPro BV |
